Stryker Corp (NYSE:SYK) stock rose 3.92% (As on August 4, 12:06:03 AM UTC-4, Source: Google Finance) after the company raised its annual profit forecast as the medtech company sees strong demand for its medical and surgical devices, aided by a post-pandemic pickup in surgical procedure volumes at hospitals. The company also beat Wall Street estimates for profit in the second quarter and became the latest in line to benefit from the recent boost to medtech businesses. In the second quarter, sales at Stryker’s medical surgery and neurotechnology unit rose 12.2%, to $2.9 billion, while sales in the orthopedics and spine segment rose nearly 10%, to $2.14 billion. The company had earlier said supply-chain pressures are gradually improving and it expects pricing to be relatively neutral for the year. Organic net sales of MedSurg and Neurotechnology increased 12.9% in the quarter including 11.5% from increased unit volume and 1.4% from higher prices. Organic net sales of Orthopaedics and Spine increased 10.6% in the quarter including 11.3% from increased unit volume partially offset by 0.7% from lower prices.
SYK in the second quarter of FY 23 has reported the adjusted earnings per share of $2.54, beating the analysts’ estimates for the adjusted earnings per share of $2.38, according to Refinitiv data. The company had reported the adjusted revenue growth of 11.2 percent to $5 billion in the second quarter of FY 23, beating the analysts’ estimates for revenue of $4.83 billion. Organic net sales increased 11.9% in the quarter including 11.4% from increased unit volume and 0.5% from higher prices. Excluding the aforementioned items, adjusted gross profit margin was 63.9% in the quarter, and adjusted operating income margin was 24.3% in the quarter. Adjusted net earnings of $976 million increased 13.5% in the quarter.
The joint-implant maker now expects a profit of $10.25 to $10.45 per share, compared to its prior forecast of between $10.05 and $10.25 per share. Analysts were expecting a profit of $10.16 for the year, according to Refinitiv IBES data. Due to strong order book for capital equipment and continued positive procedural trends, the company now expects full year 2023 organic net sales growth to be in the range of 9.5% to 10.5% including slightly positive pricing for the year.
On the other hand, Robeco Institutional Asset Management B.V. has increased its position in Stryker Co. by 31.1% in the first quarter. The firm now owns 26,565 shares of the medical technology company’s stock, worth $7,584,000.